{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-030102","form_type":"8-K","ticker":"IDXG","cik":"0001054102","company_name":"INTERPACE BIOSCIENCES, INC.","filed_at":"2024-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.040135+00:00","generated_at":"2026-05-31T13:21:44.493910+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Interpace Q2 revenue $12.0M (+9% YoY); operating income $2.2M vs $0.8M","bullets":["Test volume up 12% YoY to record levels; sixteenth consecutive quarter of YoY volume growth.","Operating income $2.2M vs $0.8M in prior-year quarter; income from continuing ops $2.1M vs $0.4M.","Adjusted EBITDA $2.3M vs $1.3M; cash collections $11.0M (+7% YoY).","Cash balance $2.0M at June 30, 2024, down from $5.1M due to $4.6M additional long-term debt paydown.","Gross profit margin stable at 62%; operating expenses down ~14% YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-030102","json":"https://secwatch.observer/filing/0001493152-24-030102.json","markdown":"https://secwatch.observer/filing/0001493152-24-030102.md","text":"https://secwatch.observer/filing/0001493152-24-030102.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1054102/000149315224030102/0001493152-24-030102-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1054102/000149315224030102/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:21:44.493910+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}